{
  "items": "11",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025",
      "url": "https://www.sahmcapital.com/news/content/prokidney-presents-full-results-from-the-phase-2-regen-007-trial-of-rilparencel-at-the-american-society-of-nephrology-kidney-week-2025-2025-11-06",
      "time_published": "20251124T140923",
      "authors": [
        "NULL"
      ],
      "summary": "ProKidney Corp. presented full results from its Phase 2 REGEN-007 trial of rilparencel at the American Society of Nephrology Kidney Week 2025. The study showed that rilparencel significantly slowed the progression of chronic kidney disease (CKD) in patients with advanced CKD and diabetes, with a 78% improvement in annual eGFR decline in Group 1. The treatment was well-tolerated, and over half of the patients for the Phase 3 accelerated approval analysis have been enrolled, with topline results anticipated in Q2 2027.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925016"
        }
      ],
      "overall_sentiment_score": 0.809028,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.824271",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ProKidney Independent Director Brian Jude Pereira Sells 100% Of Holding",
      "url": "https://www.sahmcapital.com/news/content/prokidney-independent-director-brian-jude-pereira-sells-100-of-holding-2025-11-16",
      "time_published": "20251117T045112",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "ProKidney Corp.'s Independent Director Brian Jude Pereira recently sold his entire holding in the company, netting approximately US$1.9 million. This significant insider sale, representing 100% of his shares at an average price of US$2.49, suggests a strong desire to reallocate capital, despite the sale price being above the current share price of US$2.41. The lack of recent insider purchases and a moderate insider ownership of 8.4% raise some caution regarding the company.",
      "banner_image": "https://images.simplywall.st/asset/chart/598380790-insider-trading-volume-1-dark-2/1763298093530",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.744407"
        }
      ],
      "overall_sentiment_score": -0.456292,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.485073",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates",
      "url": "https://www.globenewswire.com/news-release/2025/11/10/3185075/0/en/ProKidney-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Regulatory-and-Clinical-Updates.html",
      "time_published": "20251110T161500",
      "authors": [
        "NULL"
      ],
      "summary": "ProKidney announced its Q3 2025 financial results and provided updates on its clinical trials for rilparencel, a cell therapy for chronic kidney disease (CKD). Full Phase 2 REGEN-007 study results were presented at ASN Kidney Week 2025, demonstrating significant kidney function stabilization. Enrollment for the Phase 3 PROACT 1 study is over halfway complete, with topline results expected in Q2 2027, and the company ended the quarter with $272 million in cash, providing runway into mid-2027.",
      "banner_image": "https://ml.globenewswire.com/media/ODNkNjBhNWQtZTM4ZC00OTM4LTk2YzgtZjdmMDViNWRmZmIxLTEyNTU4MjgtMjAyNS0xMS0xMC1lbg==/tiny/ProKidney.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747308"
        }
      ],
      "overall_sentiment_score": 0.55129,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.594310",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ProKidney Corp. Reports Phase 2 REGEN-007 Study Results and Phase 3 PROACT 1 Enrollment Update at ASN Kidney Week 2025",
      "url": "https://www.quiverquant.com/news/ProKidney+Corp.+Reports+Phase+2+REGEN-007+Study+Results+and+Phase+3+PROACT+1+Enrollment+Update+at+ASN+Kidney+Week+2025",
      "time_published": "20251109T180853",
      "authors": [
        "NULL"
      ],
      "summary": "ProKidney Corp. announced positive Phase 2 results for its rilparencel treatment in patients with advanced chronic kidney disease and diabetes, showing significant improvement in kidney function. The company also provided an update on its Phase 3 PROACT 1 study, with over half of the required patients enrolled and topline results expected in Q2 2027. ProKidney reported strong financial liquidity with $272 million in cash and equivalents, sufficient to fund operations into mid-2027, despite a decrease from the previous year.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.930239"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.817511"
        },
        {
          "topic": "finance",
          "relevance_score": "0.628058"
        }
      ],
      "overall_sentiment_score": 0.48532,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "0.995520",
          "ticker_sentiment_score": "0.471116",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ProKidney Corp. to Present Late-Breaking Phase 2 REGEN-007 Study Results at ASN Kidney Week 2025",
      "url": "https://www.quiverquant.com/news/ProKidney+Corp.+to+Present+Late-Breaking+Phase+2+REGEN-007+Study+Results+at+ASN+Kidney+Week+2025",
      "time_published": "20251108T045112",
      "authors": [
        "NULL"
      ],
      "summary": "ProKidney Corp. announced it will present two posters at ASN Kidney Week 2025, including late-breaking Phase 2 REGEN-007 study results for renal autologous cell therapy in diabetes and CKD, and a characterization of its cell therapy candidate, rilparencel. These presentations aim to highlight the company's research progress in treating chronic kidney disease. The posters will be available on ProKidney's website after the event.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916031"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.738811"
        }
      ],
      "overall_sentiment_score": 0.294435,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.284199",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ProKidney Corp. Reports Positive Phase 2 Results for Rilparencel in Advanced Chronic Kidney Disease and Diabetes",
      "url": "https://www.quiverquant.com/news/ProKidney+Corp.+Reports+Positive+Phase+2+Results+for+Rilparencel+in+Advanced+Chronic+Kidney+Disease+and+Diabetes",
      "time_published": "20251106T161200",
      "authors": [],
      "summary": "ProKidney Corp. announced positive Phase 2 trial results for rilparencel, an autologous cell therapy for advanced chronic kidney disease (CKD) and diabetes, which significantly slowed CKD progression and exhibited a favorable safety profile. Rilparencel is currently the only cell therapy in Phase 3 trials for this condition, with over half of the required patient enrollment complete and topline results anticipated by Q2 2027. These findings suggest rilparencel could offer a new therapeutic option to preserve kidney function and delay dialysis for high-risk patients.",
      "banner_image": "https://quiverquant.com/images/prok_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925046"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.708906"
        }
      ],
      "overall_sentiment_score": 0.44878,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "0.952830",
          "ticker_sentiment_score": "0.421888",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing - MarketScreener",
      "url": "https://www.marketscreener.com/news/prokidney-corp-to-sell-greensboro-property-for-19-1-million-sec-filing-ce7d5adddf8cf625",
      "time_published": "20251017T210514",
      "authors": [
        "Reuters"
      ],
      "summary": "ProKidney Corp. is set to sell a property in Greensboro for $19.1 million, as disclosed in an SEC filing. This real estate transaction is a significant financial move for the clinical-stage biotechnology company. The article also provides an overview of ProKidney's recent news, including presentations at healthcare conferences and its latest earnings report.",
      "banner_image": "NULL",
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "real_estate",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.745402"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.514150"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.421261"
        }
      ],
      "overall_sentiment_score": 0.009083,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "0.307327",
          "ticker_sentiment_score": "0.024987",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ProKidney Sells Greensboro Property for $19.1 Million - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/prokidney-sells-greensboro-property-for-19-1-million",
      "time_published": "20251017T210436",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "ProKidney Corp. has agreed to sell its Greensboro property for approximately $19.1 million in cash to Northpoint Development, LLC. This sale is part of the company's strategy to manage its real estate assets effectively. Spark, TipRanks' AI Analyst, rates PROK as \"Underperform\" due to poor financial performance, weak revenue growth, high operational costs, and negative cash flow.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "real_estate",
          "relevance_score": "0.941640"
        },
        {
          "topic": "finance",
          "relevance_score": "0.611366"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.531985"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.418453"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.346583"
        }
      ],
      "overall_sentiment_score": 0.024772,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "0.337483",
          "ticker_sentiment_score": "0.024184",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ProKidney Corp. Reports First Quarter 2025 Financial Results and Key Milestones for Rilparencel Development",
      "url": "https://www.nasdaq.com/articles/prokidney-corp-reports-first-quarter-2025-financial-results-and-key-milestones-rilparencel",
      "time_published": "20250512T180853",
      "authors": [
        "NULL"
      ],
      "summary": "ProKidney Corp. reported its Q1 2025 financial results, including a net loss of $38 million and a cash position of $328.5 million sufficient to fund operations until mid-2027. The company anticipates releasing full data from its Phase 2 REGEN-007 study in Q2 2025 and expects further details on the accelerated approval pathway for rilparencel after a mid-2025 Type B meeting with the FDA, which has already confirmed the pathway's availability. ProKidney is also advancing its Phase 3 PROACT 1 study for chronic kidney disease.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.944744"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.815444"
        }
      ],
      "overall_sentiment_score": 0.135107,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.117241",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ProKidney lists Greensboro property for sale, leaving future in city uncertain",
      "url": "https://www.wfmynews2.com/article/money/business/prokidney-greensboro-sale/83-f6fb12f9-a8e2-4e1f-9fb7-c2ccc6ad702b",
      "time_published": "20241118T224400",
      "authors": [
        "Jeremy Vernon",
        "Tom Santaniello"
      ],
      "summary": "ProKidney, a Winston-Salem-based biotech company, has listed its 210,600-square-foot facility in Greensboro for sale, casting doubt on its previously announced plans to expand operations and create 330 jobs in the city. The company had planned to invest nearly half a billion dollars for the commercial manufacturing of Renal Autologous Cell Therapy, but paused manufacturing earlier this year after an audit. ProKidney states its current focus is on expanding manufacturing capabilities in Winston-Salem.",
      "banner_image": null,
      "source": "wfmynews2.com",
      "category_within_source": "General",
      "source_domain": "wfmynews2.com",
      "topics": [
        {
          "topic": "real_estate",
          "relevance_score": "0.929275"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.847985"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.705916"
        },
        {
          "topic": "economy_fiscal",
          "relevance_score": "0.642682"
        }
      ],
      "overall_sentiment_score": -0.406694,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.408220",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ProKidney drops Phase III CKD study to focus on US market and save up to $175m",
      "url": "https://www.clinicaltrialsarena.com/news/prokidney-drops-phase-iii-ckd-study-to-focus-on-us-market-and-save-up-to-175m-2/",
      "time_published": "20240904T000000",
      "authors": [
        "Jenna Philpott"
      ],
      "summary": "ProKidney has decided to discontinue its ex-US Phase III study (REGEN-016) for its chronic kidney disease (CKD) cell therapy, rilparencel, to prioritize the US market. This strategic shift, following discussions with regulatory experts, is expected to save the company between $150m and $175m, accelerating the cell therapy's availability in its highest priority market. The company will now focus its efforts on the REGEN-006 (PROACT 1) study in the US.",
      "banner_image": null,
      "source": "Clinical Trials Arena",
      "category_within_source": "General",
      "source_domain": "Clinical Trials Arena",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920764"
        }
      ],
      "overall_sentiment_score": 0.109423,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PROK",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.103699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}